Alcohol-Associated Liver Disease Investigational Treatment Study
Join a research study evaluating an investigational medication to treat alcohol-associated liver disease at the University of California, San Diego.
Click Here to See if You are Eligible
Sign Up Now
Consumed Alcohol in Past 12 Weeks
Compensation Provided
Alcohol-Associated Liver Damage
21+ Years Old
Fast Facts
Conducted in San Diego, CA
Study Background UCSD researchers are studying an investigational medication called guselkumab for patients with alcoholic liver disease. This drug is currently approved for use in psoriatic arthritis but not for alcoholic liver disease. In this study, investigators aim to assess the safety of the research treatment in those with alcoholic liver disease. If you have a current alcohol use disorder (see Is This Study For Me?), you may qualify to enroll. Your participation in this study could lead to better treatments for alcohol-associated liver disease in the future. Join our compensated research study today. |
Click Here to See if You are Eligible
Additional Information
This study aims to assess the safety and tolerability of guselkumab for people with alcohol-associated liver disease.
You may be eligible if you have an alcohol use disorder and no other possible causes of liver disease. Symptoms of alcohol use disorder may include:
- Drinking alcohol in greater amounts or for a longer time than you intended
- Trying unsuccessfully to drink less alcohol
- Spending a lot of time or effort getting alcohol, drinking alcohol, or recovering from its effects
- Strong desire to use alcohol
- Alcohol getting in the way of obligations at work, school, or home
- Continuing to drink alcohol even when you know it is causing you problems
- Tolerance (needing more alcohol to feel the same way)
During the study, you will receive two doses of guselkumab. A dose is administered on Day 1 and Day 29 of the study. Clinical and laboratory evaluations will occur around each dose. At Week 8 and Week 16, only clinical and laboratory evaluations will occur, without additional doses.
Participants will receive $50 for each completed study visit.
There is no cost to participate in this study.
For questions or additional information, please contact the study team at 858-246-2179.